TrialHuman vaccines & immunotherapeutics2014

A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children.

Christopher S Ambrose et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.